Core Viewpoint - The aging population in China is driving an increase in medical demand, particularly for anti-infection drugs, with the market expected to grow from 246.7 billion yuan in 2024 to 309 billion yuan by 2028, reflecting a compound annual growth rate (CAGR) of 5.80% [1] Industry Overview - The overall medical level in China is improving due to ongoing reforms and updates in medical policies and systems, which is contributing to the rising demand for anti-infection drugs [1] Company Positioning - China National Pharmaceutical Modern (600420.SH) has confirmed its comprehensive layout in the anti-infection industry chain, covering the entire process from pharmaceutical intermediates and raw materials to finished drugs, particularly in the penicillin and cephalosporin sectors [1]